READ MORE Press Release | September 5, 2023 Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer READ MORE VIEW ALL NEWS © 2024 Glyscend, Inc. | Privacy Policy | Terms of Use Close Menu ...
Glyscend,Inc.是一家由基于风险投资的生物制药公司,致力于开发新型口服药物,这些药物可作用于胃肠道内的靶点,治疗包括T2D在内的各种代谢性疾病。Glyscend的聚合物技术平台借鉴了约翰·霍普金斯大学的研究,即某些类型的减肥手术中有可以明显改善葡萄糖和代谢调节的机制。他们发现特别设计的聚合物经过小鼠口服进入体内后,可...